Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603081 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate SPI-1005 in Adults With Meniere's Disease
A Phase 1 study, sponsored by Sound Pharmaceuticals, Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02603081 is a Phase 1 study that has completed, run by Sound Pharmaceuticals, Incorporated. The registered enrollment target is 40 participants.
The verdict
NCT02603081, a Phase 1 study, has completed, sponsored by Sound Pharmaceuticals, Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of three dose levels of SPI-1005 compared to placebo on vertigo, tinnitus and sensorineural hearing loss in 40 adults with Meniere's disease.
Interventions
- DRUG SPI-1005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603081
The ClinicalTrials.gov registry entry for NCT02603081 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sound Pharmaceuticals, Incorporated, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPI-1005 is the first listed.
NCT02603081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02603081 about?
NCT02603081 is a clinical study titled "Study to Evaluate SPI-1005 in Adults With Meniere's Disease". This study will evaluate the safety and efficacy of three dose levels of SPI-1005 compared to placebo on vertigo, tinnitus and sensorineural hearing loss in 40 adults with Meniere's disease.
What is the current status of trial NCT02603081?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2015-12. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02603081?
The interventions under investigation include: SPI-1005 (DRUG).
Who is sponsoring clinical trial NCT02603081?
This trial is sponsored by Sound Pharmaceuticals, Incorporated, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.